Trial Profile

A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 14 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ruxolitinib (Primary) ; Cyclophosphamide; Methotrexate; Mycophenolate mofetil; Mycophenolate mofetil; Tacrolimus; Tacrolimus
Indications Graft-versus-host disease
Focus Therapeutic Use
Sponsors Incyte Corporation

02 Apr 2025 Planned initiation date (estimated date of first participant enrollment) changed from 17 Mar 2025 to 7 Apr 2025.
10 Mar 2025 Planned End Date changed from 20 Oct 2030 to 17 Jan 2031.
10 Mar 2025 Planned primary completion date changed from 20 Oct 2030 to 17 Jan 2031.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com